These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 34193378)

  • 1. Improving prostate biopsy decision making in Mexican patients: Still a major public health concern.
    Amaya-Fragoso E; García-Pérez CM
    Urol Oncol; 2021 Dec; 39(12):831.e11-831.e18. PubMed ID: 34193378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts.
    Ankerst DP; Straubinger J; Selig K; Guerrios L; De Hoedt A; Hernandez J; Liss MA; Leach RJ; Freedland SJ; Kattan MW; Nam R; Haese A; Montorsi F; Boorjian SA; Cooperberg MR; Poyet C; Vertosick E; Vickers AJ
    Eur Urol; 2018 Aug; 74(2):197-203. PubMed ID: 29778349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate cancer risk prediction in a urology clinic in Mexico.
    Liang Y; Messer JC; Louden C; Jimenez-Rios MA; Thompson IM; Camarena-Reynoso HR
    Urol Oncol; 2013 Oct; 31(7):1085-92. PubMed ID: 22306115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts.
    Drost FH; Nieboer D; Morgan TM; Carroll PR; Roobol MJ;
    Eur Urol; 2019 Nov; 76(5):693-702. PubMed ID: 31451332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
    Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
    Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator.
    Ankerst DP; Goros M; Tomlins SA; Patil D; Feng Z; Wei JT; Sanda MG; Gelfond J; Thompson IM; Leach RJ; Liss MA
    Eur Urol Focus; 2019 Jan; 5(1):54-61. PubMed ID: 29422418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.
    Ankerst DP; Boeck A; Freedland SJ; Thompson IM; Cronin AM; Roobol MJ; Hugosson J; Stephen Jones J; Kattan MW; Klein EA; Hamdy F; Neal D; Donovan J; Parekh DJ; Klocker H; Horninger W; Benchikh A; Salama G; Villers A; Moreira DM; Schröder FH; Lilja H; Vickers AJ
    World J Urol; 2012 Apr; 30(2):181-7. PubMed ID: 22210512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and External Validation of the Korean Prostate Cancer Risk Calculator for High-Grade Prostate Cancer: Comparison with Two Western Risk Calculators in an Asian Cohort.
    Park JY; Yoon S; Park MS; Choi H; Bae JH; Moon DG; Hong SK; Lee SE; Park C; Byun SS
    PLoS One; 2017; 12(1):e0168917. PubMed ID: 28046017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of the finasteride-adjusted Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator in a Mexican referral population: a validation study.
    Liang Y; Ketchum NS; Louden C; Jimenez-Rios MA; Thompson IM; Camarena-Reynoso HR
    Urol Int; 2012; 89(1):9-16. PubMed ID: 22626812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
    Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
    Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adaptation of the prostate biopsy collaborative group risk calculator in patients with PSA less than 10 ng/ml improves its performance.
    Stojadinovic M; Trifunovic T; Jankovic S
    Int Urol Nephrol; 2020 Oct; 52(10):1811-1819. PubMed ID: 32468165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay.
    Hansen J; Auprich M; Ahyai SA; de la Taille A; van Poppel H; Marberger M; Stenzl A; Mulders PF; Huland H; Fisch M; Abbou CC; Schalken JA; Fradet Y; Marks LS; Ellis W; Partin AW; Pummer K; Graefen M; Haese A; Walz J; Briganti A; Shariat SF; Chun FK
    Eur Urol; 2013 Feb; 63(2):201-9. PubMed ID: 22854248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies.
    Van Neste L; Partin AW; Stewart GD; Epstein JI; Harrison DJ; Van Criekinge W
    Prostate; 2016 Sep; 76(12):1078-87. PubMed ID: 27121847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing the prediction of prostate biopsy outcome using the Chinese Prostate Cancer Consortium (CPCC) Risk Calculator and the Asian adapted Rotterdam European Randomized Study of Screening for Prostate Cancer (ERSPC) Risk Calculator in Chinese and European men.
    Chen R; Verbeek JFM; Yang Y; Song Z; Sun Y; Roobol MJ
    World J Urol; 2021 Jan; 39(1):73-80. PubMed ID: 32279141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of prostate cancer prediction models in men undergoing both magnetic resonance imaging and transperineal biopsy: Are the models still relevant?
    Doan P; Graham P; Lahoud J; Remmers S; Roobol MJ; Kim L; Patel MI
    BJU Int; 2021 Dec; 128 Suppl 3():36-44. PubMed ID: 34374190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative effectiveness analysis of the PBCG vs. PCPT risks calculators in a multi-ethnic cohort.
    Carbunaru S; Nettey OS; Gogana P; Helenowski IB; Jovanovic B; Ruden M; Hollowell CMP; Sharifi R; Kittles RA; Schaeffer E; Gann P; Murphy AB
    BMC Urol; 2019 Nov; 19(1):121. PubMed ID: 31771578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers in previous histologically negative prostate biopsies can be helpful in repeat biopsy decision-making processes.
    Long X; Wu L; Zeng X; Wu Z; Hu X; Jiang H; Lv Z; Yang C; Cai Y; Yang K; Li Y
    Cancer Med; 2020 Oct; 9(20):7524-7536. PubMed ID: 32860339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate Cancer Risk Calculator Apps in a Taiwanese Population Cohort: Validation Study.
    Chen IA; Chu CH; Lin JT; Tsai JY; Yu CC; Sridhar AN; Sooriakumaran P; Loureiro RCV; Chand M
    J Med Internet Res; 2020 Dec; 22(12):e16322. PubMed ID: 33337340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A risk calculator to inform the need for a prostate biopsy: a rapid access clinic cohort.
    Jalali A; Foley RW; Maweni RM; Murphy K; Lundon DJ; Lynch T; Power R; O'Brien F; O'Malley KJ; Galvin DJ; Durkan GC; Murphy TB; Watson RW
    BMC Med Inform Decis Mak; 2020 Jul; 20(1):148. PubMed ID: 32620120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are prostate biopsies necessary for all patients 75years and older?
    Chen Y; Fan Y; Yang Y; Jin J; Zhou L; He Z; Zhao Z; He Q; Wang X; Yu W; Wu S
    J Geriatr Oncol; 2018 Mar; 9(2):124-129. PubMed ID: 28939384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.